Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Recruiting · NCT06824818 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Chicago
View the official record on ClinicalTrials.gov →Interventions studied
LHRH Agonist Therapy Discontinuation
What this trial is about
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Who can take part
Age range
70 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Prostate cancer with \>3 years of LHRH agonist therapy.
- Age ≥70 years.
- ECOG performance status ≤2
- Baseline testosterone of \< 20 ng/ml
- No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
- Ability to understand and sign informed consent.
Exclusion criteria
- none
Where it is running
2 locations listed across 1 US state.
- The University of Illinois at Chicago (UIC) - Chicago, Illinois, United States
- UChicago Medicine Comprehensive Cancer Center - Chicago, Illinois, United States